UBS downgraded CME Group (CME) to Neutral from Buy with an unchanged price target of $305. The firm cites valuation for the downgrade with the shares up 19% year-to-date. Geopolitical uncertainty drove volumes and CME shares higher over the past year, but trading activity has started to slow recently, the analyst tells investors in a research note. UBS does not see increased retail trading leading to significant near-term upside for the company. It reduced estimates for CME below consensus for fiscal 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CME:
- CME Group price target raised to $303 from $300 at Oppenheimer
- Positive Outlook for CME Group Driven by Risk Management Demand and Strong Financial Position
- CME Group price target lowered to $298 from $299 at Barclays
- CME Group Inc. Reports Record Q2 2025 Earnings
- CME Group reports Q2 adjusted EPS $2.96, consensus $2.92